These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14526311)

  • 1. Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis.
    Doyle NM; Gardner MO
    Am J Obstet Gynecol; 2003 Sep; 189(3):769-74. PubMed ID: 14526311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of antenatal screening for cystic fibrosis.
    Cuckle HS; Richardson GA; Sheldon TA; Quirke P
    BMJ; 1995 Dec; 311(7018):1460-3; discussion 1463-4. PubMed ID: 8520332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis.
    Vintzileos AM; Ananth CV; Smulian JC; Fisher AJ; Day-Salvatore D; Beazoglou T
    Obstet Gynecol; 1998 Apr; 91(4):529-34. PubMed ID: 9540935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of prenatal carrier screening for fragile X syndrome.
    Vintzileos AM; Ananth CV; Fisher AJ; Smulian JC; Day-Salvatore D; Beazoglou T; Knuppel RA
    J Matern Fetal Med; 1999; 8(4):168-72. PubMed ID: 10406300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic fibrosis screening at the Greenville Hospital System.
    Dacus J; Mabie B; Gailey T; Rogers C; Likes C; Metcalf L
    J S C Med Assoc; 2006 Feb; 102(1):14-6. PubMed ID: 16704181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal screening for cystic fibrosis: an economic analysis.
    Nielsen R; Gyrd-Hansen D
    Health Econ; 2002 Jun; 11(4):285-99. PubMed ID: 12007162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.
    Layde PM; von Allmen SD; Oakley GP
    Am J Public Health; 1979 Jun; 69(6):566-73. PubMed ID: 87134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal screening for cystic fibrosis carriers: an economic evaluation.
    Rowley PT; Loader S; Kaplan RM
    Am J Hum Genet; 1998 Oct; 63(4):1160-74. PubMed ID: 9758600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and benefits of prenatal screening for cystic fibrosis.
    Garber AM; Fenerty JP
    Med Care; 1991 May; 29(5):473-89. PubMed ID: 1673488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
    Ohno M; Caughey A
    Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost utility of prenatal diagnosis and the risk-based threshold.
    Harris RA; Washington AE; Nease RF; Kuppermann M
    Lancet; 2004 Jan; 363(9405):276-82. PubMed ID: 14751700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing value for money in medical screening.
    Cairns JA; Shackley P
    J Med Screen; 1994 Jan; 1(1):39-44. PubMed ID: 8790484
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.
    Ginsberg G; Blau H; Kerem E; Springer C; Kerem BS; Akstein E; Greenberg A; Kolumbos A; Abeliovich D; Gazit E
    Health Econ; 1994; 3(1):5-23. PubMed ID: 8167800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis.
    Maxwell S; Brameld K; Youngs L; Geelhoed E; O'Leary P
    Aust N Z J Obstet Gynaecol; 2010 Feb; 50(1):51-9. PubMed ID: 20218998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of prenatal strategies for detection of trisomy 18.
    Vintzileos AM; Ananth CV; Fisher AJ; Smulian JC; Day-Salvatore D; Beazoglou T; Knuppel RA
    Am J Obstet Gynecol; 1998 Nov; 179(5):1220-4. PubMed ID: 9822504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
    Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
    Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues in implementing prenatal screening for cystic fibrosis: results of a working conference.
    Haddow JE; Bradley LA; Palomaki GE; Doherty RA
    J Med Screen; 1999; 6(2):60-6. PubMed ID: 10444721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.